Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.40 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.40 |
| ▸ | PNMT | P11086 | 2/20 | 0.36 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.33 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.32 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.32 |
| ▸ | CXCR1 | P25024 | 2/20 | 0.32 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.32 |
| ▸ | ALB | P02768 | 1/20 | 0.32 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15067851 | 0.79 | GABRA1 (0.42) | GABRA1GABRB2AKR1C2FAAHMEN1 | |
| SCHEMBL677764 | 0.78 | GABRA1 (0.41) | GABRA1GABRB2AKR1C2FAAHMEN1 | |
| SCHEMBL7469143 | 0.78 | GABRA1 (0.41) | GABRA1GABRB2AKR1C2FAAHMEN1 | |
| SCHEMBL455325 | 0.77 | — | — | |
| SCHEMBL27370589 | 0.76 | GABRA1 (0.40) | GABRA1GABRB2PNMTAKR1C2MEN1 | |
| SCHEMBL921395 | 0.76 | GABRA1 (0.40) | GABRA1GABRB2AKR1C2MEN1POLB | |
| SCHEMBL165772 | 0.76 | GABRA1 (0.40) | GABRA1GABRB2AKR1C2MEN1POLB | |
| SCHEMBL1859206 | 0.74 | PNMT (0.36) | GABRA1GABRB2PNMTAKR1C2AKR1C1 | |
| SCHEMBL10367130 | 0.74 | — | — | |
| SCHEMBL2005701 | 0.73 | CNR2 (0.39) | POLBMAPTALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117342938-A | Preparation method of ibuprofen | 常州大学 | 2024-01-05 | — | — | CN | claimed |
| CN-117342938-A | Preparation method of ibuprofen | 常州大学 | 2024-01-05 | — | — | CN | disclosed |
| US-6911469-B2 | Sulfonamide compounds and pharmaceutical use thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-06-28 | — | — | US | disclosed |
| US-20040180947-A1 | hypoglycemic activity or phoshodiesterase-V inhibitory activity; prophylaxis and treatment of impaired glucose tolerance disorder, diabetes (e.g., type II diabetes), diabetic complications | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-09-16 | — | — | US | disclosed |
| US-20020099212-A1 | For therapy of disease treatable based on a blood sugar level-depressing activity or a disease treatable based on a cGMP-PDE inhibiting activity, smooth muscle relaxing activity, bronchodilating activity, vasodilating activity | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2002-07-25 | — | — | US | disclosed |
| CN-1268942-A | Sulfonamide compounds and medicinal use thereof | FUJISAWA PHARMACEUTICAL CO (JP) | 2000-10-04 | — | — | CN | disclosed |
| EP-0995742-A1 | SULFONAMIDE COMPOUNDS AND MEDICINAL USE THEREOF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-04-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020099212-A1 | For therapy of disease treatable based on a blood sugar level-depressing activity or a disease treatable based on a cGMP-PDE inhibiting activity, smooth muscle relaxing activity, bronchodilating activity, vasodilating activity | PDE2A, PDE3A, PDE12 | GABRA1 555/4885GABRB2 341/4885PNMT 836/4885 |
| US-20040180947-A1 | hypoglycemic activity or phoshodiesterase-V inhibitory activity; prophylaxis and treatment of impaired glucose tolerance disorder, diabetes (e.g., type II diabetes), diabetic complications | PDE2A, PDE3A, PYGM | GABRA1 1185/4885GABRB2 545/4885PNMT 1289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.